202 related articles for article (PubMed ID: 33995678)
1. Targeting hyperactive TGFBR2 for treating MYOCD deficient lung cancer.
Zhou Q; Chen W; Fan Z; Chen Z; Liang J; Zeng G; Liu L; Liu W; Yang T; Cao X; Yu B; Xu M; Chen YG; Chen L
Theranostics; 2021; 11(13):6592-6606. PubMed ID: 33995678
[No Abstract] [Full Text] [Related]
2. Inactivation of tumor suppressor gene Clusterin leads to hyperactivation of TAK1-NF-κB signaling axis in lung cancer cells and denotes a therapeutic opportunity.
Chen Z; Fan Z; Dou X; Zhou Q; Zeng G; Liu L; Chen W; Lan R; Liu W; Ru G; Yu L; He QY; Chen L
Theranostics; 2020; 10(25):11520-11534. PubMed ID: 33052230
[No Abstract] [Full Text] [Related]
3. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
4. YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer.
Lo Sardo F; Pulito C; Sacconi A; Korita E; Sudol M; Strano S; Blandino G
Cancer Lett; 2021 Mar; 500():51-63. PubMed ID: 33296708
[TBL] [Abstract][Full Text] [Related]
5. A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.
Chen H; Lorton B; Gupta V; Shechter D
Oncogene; 2017 Jan; 36(3):373-386. PubMed ID: 27270440
[TBL] [Abstract][Full Text] [Related]
6. Targeted gene-silencing reveals the functional significance of myocardin signaling in the failing heart.
Torrado M; Iglesias R; Centeno A; López E; Mikhailov AT
PLoS One; 2011; 6(10):e26392. PubMed ID: 22028870
[TBL] [Abstract][Full Text] [Related]
7. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Sox2 and stemness by nicotine and electronic-cigarettes in non-small cell lung cancer.
Schaal CM; Bora-Singhal N; Kumar DM; Chellappan SP
Mol Cancer; 2018 Oct; 17(1):149. PubMed ID: 30322398
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of DNMT3A by miR-708-5p Inhibits Lung Cancer Stem Cell-like Phenotypes through Repressing Wnt/β-catenin Signaling.
Liu T; Wu X; Chen T; Luo Z; Hu X
Clin Cancer Res; 2018 Apr; 24(7):1748-1760. PubMed ID: 28972040
[No Abstract] [Full Text] [Related]
10. Metformin reduces HGF-induced resistance to alectinib via the inhibition of Gab1.
Chen H; Lin C; Peng T; Hu C; Lu C; Li L; Wang Y; Han R; Feng M; Sun F; He Y
Cell Death Dis; 2020 Feb; 11(2):111. PubMed ID: 32041944
[TBL] [Abstract][Full Text] [Related]
11. Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Choi JM; Jang JY; Choi YR; Kim HR; Cho BC; Lee HW
Lung Cancer; 2015 Nov; 90(2):175-81. PubMed ID: 26342551
[TBL] [Abstract][Full Text] [Related]
12. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
13. Tyr1068-phosphorylated epidermal growth factor receptor (EGFR) predicts cancer stem cell targeting by erlotinib in preclinical models of wild-type EGFR lung cancer.
Sette G; Salvati V; Mottolese M; Visca P; Gallo E; Fecchi K; Pilozzi E; Duranti E; Policicchio E; Tartaglia M; Milella M; De Maria R; Eramo A
Cell Death Dis; 2015 Aug; 6(8):e1850. PubMed ID: 26247735
[TBL] [Abstract][Full Text] [Related]
14. [CRAF, a key player in lung adenocarcinomas induced by K-Ras oncogene].
Francoz S; Dubus P
Med Sci (Paris); 2011 Oct; 27(10):820-2. PubMed ID: 22027418
[No Abstract] [Full Text] [Related]
15. PCC0208027, a novel tyrosine kinase inhibitor, inhibits tumor growth of NSCLC by targeting EGFR and HER2 aberrations.
Dong Q; Yu P; Ye L; Zhang J; Wang H; Zou F; Tian J; Kurihara H
Sci Rep; 2019 Apr; 9(1):5692. PubMed ID: 30952931
[TBL] [Abstract][Full Text] [Related]
16. MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancers Expressing Wild-type
Yan D; Parker RE; Wang X; Frye SV; Earp HS; DeRyckere D; Graham DK
Clin Cancer Res; 2018 Dec; 24(24):6523-6535. PubMed ID: 30194074
[TBL] [Abstract][Full Text] [Related]
17. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
Zhang K; Yuan Q
J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
[TBL] [Abstract][Full Text] [Related]
18. The repression and reciprocal interaction of DNA methyltransferase 1 and specificity protein 1 contributes to the inhibition of MET expression by the combination of Chinese herbal medicine FZKA decoction and erlotinib.
Zheng F; Zhao Y; Li X; Tang Q; Wu J; Wu W; Hann SS
J Ethnopharmacol; 2019 Jul; 239():111928. PubMed ID: 31077779
[TBL] [Abstract][Full Text] [Related]
19. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
Mittal V
Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.
Sawai A; Chandarlapaty S; Greulich H; Gonen M; Ye Q; Arteaga CL; Sellers W; Rosen N; Solit DB
Cancer Res; 2008 Jan; 68(2):589-96. PubMed ID: 18199556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
